Compare Stocks → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ALDXNASDAQ:KALVNASDAQ:LXRXNASDAQ:VERU Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALDXAldeyra Therapeutics$4.16-1.2%$3.70$1.42▼$11.97$247.15M1.45588,668 shs319,625 shsKALVKalVista Pharmaceuticals$12.13-0.3%$12.12$7.21▼$16.88$511.77M0.92353,364 shs199,657 shsLXRXLexicon Pharmaceuticals$1.74+2.4%$2.12$0.92▼$3.79$428.46M1.383.06 million shs5.87 million shsVERUVeru$1.63-0.6%$0.93$0.36▼$1.92$238.60M-0.474.18 million shs2.92 million shsElon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALDXAldeyra Therapeutics-1.19%+5.85%+0.24%+30.82%-59.14%KALVKalVista Pharmaceuticals-0.33%+12.52%+7.73%-20.30%+32.28%LXRXLexicon Pharmaceuticals+2.35%+10.13%-14.71%-18.31%-36.50%VERUVeru-0.61%+28.35%+96.62%+226.00%+28.35%Investors Alert: The Next Big Thing in Weight Loss (Ad)UBS bank predicts it will become "The Biggest Drug Ever." The Wall Street Journal believes it will be "Pharma's biggest blockbuster yet." Bank of America predicts it will be the world's first "$100 billion dollar a year drug." And Morgan Stanley predicts 250 million prescriptions will be written each year. Get the name of the stock here >>> MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALDXAldeyra Therapeutics1.5767 of 5 stars3.52.00.00.01.62.50.0KALVKalVista Pharmaceuticals4.0013 of 5 stars3.51.00.04.62.42.50.6LXRXLexicon Pharmaceuticals2.0029 of 5 stars3.33.00.00.01.81.70.6VERUVeru1.2798 of 5 stars3.41.00.00.02.91.70.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALDXAldeyra Therapeutics3.00Buy$9.33124.36% UpsideKALVKalVista Pharmaceuticals3.00Buy$25.00106.10% UpsideLXRXLexicon Pharmaceuticals2.67Moderate Buy$5.00187.36% UpsideVERUVeru2.75Moderate Buy$3.33104.50% UpsideCurrent Analyst RatingsLatest VERU, ALDX, LXRX, and KALV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/3/2024KALVKalVista PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$24.00 ➝ $20.005/3/2024LXRXLexicon PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold5/1/2024KALVKalVista PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.004/30/2024LXRXLexicon PharmaceuticalsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform4/30/2024LXRXLexicon PharmaceuticalsSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$5.004/23/2024LXRXLexicon PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold4/15/2024VERUVeruOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$7.00 ➝ $5.004/11/2024KALVKalVista PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.004/11/2024LXRXLexicon PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold4/3/2024ALDXAldeyra TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$10.004/2/2024ALDXAldeyra TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALDXAldeyra TherapeuticsN/AN/AN/AN/A$2.04 per shareN/AKALVKalVista PharmaceuticalsN/AN/AN/AN/A$4.71 per shareN/ALXRXLexicon Pharmaceuticals$1.20M357.05N/AN/A$0.38 per share4.58VERUVeru$16.30M14.64N/AN/A$0.22 per share7.41Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALDXAldeyra Therapeutics-$37.54M-$0.51N/AN/AN/AN/A-24.16%-19.95%8/1/2024 (Estimated)KALVKalVista Pharmaceuticals-$92.91M-$3.15N/AN/AN/AN/A-86.06%-72.65%7/5/2024 (Estimated)LXRXLexicon Pharmaceuticals-$177.12M-$0.83N/AN/AN/A-8,311.12%-137.53%-70.04%8/1/2024 (Estimated)VERUVeru-$93.15M-$0.75N/AN/AN/A-405.04%-257.92%-107.27%5/8/2024 (Confirmed)Latest VERU, ALDX, LXRX, and KALV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2024N/AVERUVeru-$0.06N/A+$0.06N/AN/AN/A 4/1/2024Q1 2024VERUVeruN/A-$0.09-$0.09-$0.10N/A$2.14 million3/11/2024Q3 2024KALVKalVista Pharmaceuticals-$0.75-$0.84-$0.09-$0.84N/AN/A3/11/2024Q4 2023LXRXLexicon Pharmaceuticals-$0.23-$0.20+$0.03-$0.20$0.68 million$0.70 million3/7/2024Q4 2023ALDXAldeyra Therapeutics-$0.21-$0.08+$0.13-$0.08N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALDXAldeyra TherapeuticsN/AN/AN/AN/AN/AKALVKalVista PharmaceuticalsN/AN/AN/AN/AN/ALXRXLexicon PharmaceuticalsN/AN/AN/AN/AN/AVERUVeruN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALDXAldeyra TherapeuticsN/A6.646.64KALVKalVista PharmaceuticalsN/A5.445.44LXRXLexicon Pharmaceuticals1.075.605.58VERUVeruN/A3.212.79OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALDXAldeyra Therapeutics59.71%KALVKalVista PharmaceuticalsN/ALXRXLexicon Pharmaceuticals74.70%VERUVeru47.16%Insider OwnershipCompanyInsider OwnershipALDXAldeyra Therapeutics7.30%KALVKalVista Pharmaceuticals12.30%LXRXLexicon Pharmaceuticals6.80%VERUVeru14.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALDXAldeyra Therapeutics1559.41 million55.08 millionOptionableKALVKalVista Pharmaceuticals11842.19 million37.00 millionOptionableLXRXLexicon Pharmaceuticals285246.24 million229.49 millionOptionableVERUVeru189146.38 million125.60 millionOptionableVERU, ALDX, LXRX, and KALV HeadlinesSourceHeadlineAnalysts Offer Insights on Healthcare Companies: Veru (VERU) and GH Research (GHRS)markets.businessinsider.com - May 3 at 11:46 PMVeru (VERU) to Release Quarterly Earnings on Wednesdaymarketbeat.com - May 2 at 9:59 AMVeru to Present at the GLP-1 Based Therapeutics Summitglobenewswire.com - May 2 at 8:30 AMHospitals inquiry concluded, 78 boxes of evidence passed on to Attorney Generalmaltatoday.com.mt - May 1 at 9:06 AMVeru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024globenewswire.com - May 1 at 8:30 AMVeru (NASDAQ:VERU) Share Price Passes Above Two Hundred Day Moving Average of $0.78americanbankingnews.com - May 1 at 3:30 AMVeru Inc. (VERU) Just Flashed Golden Cross Signal: Do You Buy?zacks.com - April 30 at 10:56 AMVeru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Lossglobenewswire.com - April 30 at 8:30 AMPalisade Capital Management Welcomes Chris Mashia to Small Cap Core and Smid Cap Core Equity Strategiesfinance.yahoo.com - April 30 at 12:33 AMVeru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11globenewswire.com - April 25 at 8:30 AMNetflix To Stop Sharing Subscriber Data; Stock Dipsmarkets.businessinsider.com - April 19 at 6:13 PMWhat Makes Veru (VERU) a New Buy Stockzacks.com - April 17 at 1:01 PMVeru (NASDAQ:VERU) Earns "Outperform" Rating from Oppenheimermarketbeat.com - April 15 at 8:29 AMREVEALED: Transport Malta officials at centre of maritime fines corruption racketmaltatoday.com.mt - April 2 at 12:43 AMVeru Announces Date of 2024 Annual Meeting of Shareholdersfinance.yahoo.com - April 1 at 7:43 PMFlag carrier Air Malta ceases operations today, its 50th birthdaymaltatoday.com.mt - March 31 at 6:39 PMVeru Incmorningstar.com - March 29 at 9:35 PMUpdated | Mosta trees vandalised: ERA, police investigatingmaltatoday.com.mt - March 29 at 8:54 AMR&B Realty’s Gateway at Wynwood hit with foreclosure lawsuittherealdeal.com - March 22 at 6:18 PMVeru Reschedules Annual Meeting of Shareholdersglobenewswire.com - March 22 at 4:05 PMWynwood offices targeted in $102M foreclosurebizjournals.com - March 21 at 6:43 PMNaksha Saran plays a bike taxi driver in her next filmmsn.com - March 19 at 4:27 AMPrecise and efficient cutting (sawing) of lightweight core materialsjeccomposites.com - March 18 at 1:24 PMVERU Mar 2024 0.500 putca.finance.yahoo.com - March 16 at 1:30 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAldeyra TherapeuticsNASDAQ:ALDXAldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.KalVista PharmaceuticalsNASDAQ:KALVKalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.Lexicon PharmaceuticalsNASDAQ:LXRXLexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.VeruNASDAQ:VERUVeru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.